See today's BioWorldSee today's BioWorld Asia
To read the full article sign up for free or sign in.

Carsgen out-licenses China rights to Huadong for BCMA CAR T for $152M

Jan. 17, 2023
By Tamra Sami
CAR T specialist Carsgen Therapeutics Holdings Ltd. out-licensed commercial rights for its B-cell maturation antigen (BCMA) CAR T therapy, CT-053, in mainland China to Huadong Medicine Co Ltd. in a deal worth up to $152 million.
BioWorld BioWorld Asia Deals and M&A License Asia-Pacific China